PHOTREXA VISCOUS
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $2.3M | 1,089 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 1,089 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | Glaukos Corporation | $2.3M | 0 |
| Observational Registry to Assess the Durability of Effect of Corneal Colagen Cross-linking | Glaukos Corporation | $37,742 | 0 |
Top Doctors Receiving Payments for PHOTREXA VISCOUS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | West Chester, OH | $2.3M | 1,089 |
Manufacturing Companies
- Glaukos Corporation $2.3M
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 0
- Transactions 1,089
About PHOTREXA VISCOUS
PHOTREXA VISCOUS is a drug associated with $2.3M in payments to 0 healthcare providers, recorded across 1,089 transactions in the CMS Open Payments database. The primary manufacturer is Glaukos Corporation.
Payment data is available from 2023 to 2023. In 2023, $2.3M was paid across 1,089 transactions to 0 doctors.
The most common payment nature for PHOTREXA VISCOUS is "Unspecified" ($2.3M, 100.0% of total).
PHOTREXA VISCOUS is associated with 2 research studies, including "A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus" ($2.3M).